Human epidermal growth factor receptor 2 overexpression is frequently discordant between primary and metastatic urothelial carcinoma and is associated with intratumoral human epidermal growth factor receptor 2 heterogeneity-Reference-Cited by-同舟云学术

Human epidermal growth factor receptor 2 overexpression is frequently discordant between primary and metastatic urothelial carcinoma and is associated with intratumoral human epidermal growth factor receptor 2 heterogeneity

Published:2021-01 Issue: Volume:107 Page:96-103
ISSN:0046-8177
Container-title:Human Pathology
language:en
Short-container-title:Human Pathology

Author:

Grigg Claud M.^ORCID,Livasy Chad,He Jiaxian,Hartman Aaron,Clark Peter E.^ORCID,Zhu Jason,Raghavan Derek,Burgess Earle F.

Funder

Don and Betty Anderson Fund

5MPower Foundation

Carolinas Bladder Cancer Fund

Leon Levine Foundation

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference37 articles.

1. HER2 expression status in diverse cancers: review of results from 37,992 patients;Yan;Canc Metastasis Rev,2015

2. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients;Lae;Ann Oncol,2010

3. HER2-targeted therapies — a role beyond breast cancer;Oh;Nat Rev Clin Oncol,2019

4. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu–positive urothelial carcinoma: results of a multicenter phase II national cancer Institute trial;Hussain;J Clin Oncol,2007

5. Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer;Powles;J Clin Oncol,2017

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis;Critical Reviews in Oncology/Hematology;2024-04

2. Antibody–drug conjugates in urothelial carcinoma: scientometric analysis and clinical trials analysis;Frontiers in Oncology;2024-03-14

3. HER2 Affects the Biological Behaviours of Bladder Cancer Cells and is Closely Associated with the Progression and Prognosis of Bladder Cancer;Archivos Españoles de Urología;2024

4. Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18;ESMO Open;2023-08

5. Moving Molecular Oncology Into Community Practice: Follow the Yellow Brick Road;JCO Oncology Practice;2023-08